Vanda Pharmaceuticals Inc
VNDA
Market Cap$246.26M
Close$
$5.76
39.9% upside
Current Fair Value
39.9% upsideUndervalued by 39.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $246.26 Million |
|---|---|
| Enterprise Value | $-142,003,504.00 |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.04 |
| Beta | 0.73 |
| Outstanding Shares | 57,537,499 |
| Avg 30 Day Volume | 3,940,991 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 98.15 |
|---|---|
| PEG | -72.71 |
| Price to Sales | 1.37 |
| Price to Book Ratio | 0.46 |
| Enterprise Value to Revenue | -0.74 |
| Enterprise Value to EBIT | 10.18 |
| Enterprise Value to Net Income | -57 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Vanda Pharmaceuticals Inc
CEO: Mihael Polymeropoulos Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.